Tani M; Fina M; Alinari L; Stefoni V; Baccarani M; Zinzani PL., Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma., «HAEMATOLOGICA», 2005, 90, pp. 1283 - 1284 [articolo]
CASTELLUCCI P.; NANNI C.; FARSAD M.; ALINARI L.; ZINZANI P.; STEFONI V.; BATTISTA G.; VALENTINI D.; PETTINATO C.; MARENGO M.; BOSCHI S.; CANINI R.; BACCARANI M.; MONETTI N.; FRANCHI R.; RAMPIN L.; FANTI S.; RUBELLO D., Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation., «NUCLEAR MEDICINE COMMUNICATIONS», 2005, 26, pp. 689 - 694 [articolo]
ZINZANI PL; ALINARI L; TANI M; FINA M; PILERI S; BACCARANI M., Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma., «HAEMATOLOGICA», 2005, 90, pp. 702 - 703 [articolo]
RAMBALDI A; CARLOTTI E; OLDANI E; DELLA STARZA I; BACCARANI M.; CORTELAZZO S; LAURIA F; ARCAINI L; MORRA E; PULSONI A; RIGACCI L; RUPOLO M; ZAJA F; ZINZANI PL; BARBUI T; FOA R., Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma., «BLOOD», 2005, 105, pp. 3428 - 3433 [articolo]
ZINZANI P.; ALINARI L; STEFONI V; LOFFREDO A; PICHIERRI P; POLITO E., Rituximab in primary conjunctiva lymphoma., «LEUKEMIA RESEARCH», 2005, 29(1), pp. 107 - 108 [articolo]
Zinzani PL; Tani M; Alinari L;Molinari AL;Stefoni V.;Visani G.; Gentilini P.; Guardigni L.; Fina M.; Baccarani M., Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy., «LEUKEMIA & LYMPHOMA», 2005, 46, pp. 1449 - 1454 [articolo]
Pileri S.A.; Piccaluga P.P.; Sabattini E.; Zinzani P.L., The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis, «HAEMATOLOGICA», 2005, 90(3), pp. 293 - 293 [articolo]Open Access
HAGEMEISTER F; CABANILLAS F; COLEMAN M; GREGORY SA; ZINZANI P., The role of mitoxantrone in the treatment of indolent lymphomas., «ONCOLOGY», 2005, 10(2), pp. 150 - 159 [articolo]
Zucca E.; Zinzani PL., Understanding the group of peripheral T-cell lymphomas, unspecified., «CURRENT HEMATOLOGY REPORTS», 2005, 4, pp. 23 - 30 [articolo]
Alinari L; Musuraca G; Tani M; Stefoni V; Gabriele A; Marchi E; Fina M; De Vivo A; Pileri S; Baccarani M; Zinzani PL, Value of oxaliplatin treatment in heavily pretreated patients with
non-Hodgkin's lymphoma., «LEUKEMIA & LYMPHOMA», 2005, 46, pp. 1437 - 1440 [articolo]
CASTELLUCCI P; ZINZANI P; NANNI C; FARSAD M; MORETTI A; ALINARI L; BATTISTA G; PETTINATO C; MARENGO M; BOSCHI S; CANINI R; BACCARANI M.; MONETTI N; FANTI S., 18F-FDG PET early after radiotherapy in lymphoma patients., «CANCER BIOTHERAPY & RADIOPHARMACEUTICALS», 2004, 19, pp. 606 - 612 [articolo]
BENDANDI M; PILERI SA; ZINZANI P., Challenging paradigms in lymphoma treatment, «ANNALS OF ONCOLOGY», 2004, 15 (5), pp. 703 - 711 [articolo]
Zinzani PL., Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma, «HEMATOLOGY JOURNAL», 2004, 5, pp. S38 - S49 [articolo]
ASCANI S; WENT P; LIBERATI AM; PICCALUGA PP; ZINZANI P.; PILERI SA, Difficult diagnostic and therapeutic cases: CASE 1. true thymic hyperplasia in a patient treated for T-cell lymphoma, «JOURNAL OF CLINICAL ONCOLOGY», 2004, 22 (5), pp. 953 - 954 [articolo]
Zinzani P.L.; Pulsoni A.; Gentilini P.; Visani G.; Perrotti A.; Molinari A.L.; Guardigni L.; Tani M.; Valliva N.; Stefoni V.; Alinari L.; Martelli M.; Bonifazi F.; Pileri S.; Tura S.; Baccarani M., Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma., «LEUKEMIA & LYMPHOMA», 2004, 45, pp. 1815 - 1816 [articolo]
